Open AccessAbstract 193: The tumor microenvironment protects against ibrutinib but not rituximab-mediated control of Waldenström macroglobulinemia (WM) in vivo
Author(s) -
Weiguo Han,
Brandon Sklavanitis,
David A. Jackson,
Stephan J. Matissek,
Sherine F. Elsawa
Publication year - 2018
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2018-193
Subject(s) - ibrutinib , waldenstrom macroglobulinemia , rituximab , medicine , bruton's tyrosine kinase , tumor microenvironment , chronic lymphocytic leukemia , cancer research , stromal cell , immunology , macroglobulinemia , cd20 , in vivo , lymphoma , leukemia , cancer , multiple myeloma , biology , receptor , tyrosine kinase , microbiology and biotechnology